Telomir Pharmaceuticals, Inc. (TELO:NASDAQ) closed at $0.975 on October 23, 2026, down 1.52% on the day. The stock trades 38.3% below its 52-week high of $1.58 and 9.8% above its 52-week low of $0.888. Over the past year, it lost 35.0%. Telomir Pharmaceuticals, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, TELO closed higher on 109 days (43%). Its best day was July 21, 2026 (+17.52%) and its worst was July 20, 2026 (-17.21%). The stock moved 10% or more in a single session 5 times.
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis.
Find more stocks like TELO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.